drugset / Trial / NCT00818259
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will determine the appropriate dosing regimen of aprepitant and fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric participants from 0 months to 17 years of age.
Timeline
- Start
- 2009-02-05
- Primary completion
- 2014-01-20
- Completion
- 2014-01-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aprepitant | Other / unclassified | 0.5 mg/kg | Oral |
| Subject | Aprepitant | Other / unclassified | 0.75 mg/kg | Oral |
| Subject | Aprepitant | Other / unclassified | 1 mg/kg | Oral |
| Subject | Aprepitant | Other / unclassified | 1.3 mg/kg | Oral |
| Subject | Aprepitant | Other / unclassified | 1.5 mg/kg | Oral |
| Subject | Aprepitant | Other / unclassified | 2 mg/kg | Oral |
| Subject | Aprepitant | Other / unclassified | 3 mg/kg | Oral |
| Subject | Aprepitant | Other / unclassified | 47 mg/m2 | Oral |
| Subject | Aprepitant | Other / unclassified | 74 mg/m2 | Oral |
| Subject | Aprepitant | Other / unclassified | 80 mg | Oral |
| Subject | Fosaprepitant | Other / unclassified | 3 mg/kg | Intravenous |
| Subject | Fosaprepitant | Other / unclassified | 115 mg | Intravenous |
| Subject | Fosaprepitant | Other / unclassified | 150 mg | Intravenous |
| Background | Dexamethasone | Small molecule | — | Intravenous |
| Comparator | Ondansetron | Other / unclassified | — | Intravenous |